Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, <scp>HER2</scp> ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates

Hiroko Shimada, Maki Todo, Hiroshi Ishiguro, Emi Mikami, Wakako Inohana, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Yuki Ichinose, Akihiro Fujimoto, Asami Nukui, Aya Asano, Hideki Yokogawa, Masahiro Ohara, Kazuo Matsuura, Takahiro Hasebe, Nobuko Fujiuchi, Akihiko Osaki, Toshiaki Saeki

Open source

DOI: 10.1002/cam4.72457
Published: 2026-11
Container: Cancer Medicine
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.72457,
  title = {Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive,
                    <scp>HER2</scp>
                    ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates},
  author = {Hiroko Shimada and Maki Todo and Hiroshi Ishiguro and Emi Mikami and Wakako Inohana and Taeko Kurosawa and Ayako Nakame and Ayaka Sakakibara and Yuki Ichinose and Akihiro Fujimoto and Asami Nukui and Aya Asano and Hideki Yokogawa and Masahiro Ohara and Kazuo Matsuura and Takahiro Hasebe and Nobuko Fujiuchi and Akihiko Osaki and Toshiaki Saeki},
  year = {2026},
  journal = {Cancer Medicine},
  doi = {10.1002/cam4.72457},
  url = {https://doi.org/10.1002/cam4.72457}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive,
                    <scp>HER2</scp>
                    ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates
AU  - Hiroko Shimada
AU  - Maki Todo
AU  - Hiroshi Ishiguro
AU  - Emi Mikami
AU  - Wakako Inohana
AU  - Taeko Kurosawa
AU  - Ayako Nakame
AU  - Ayaka Sakakibara
AU  - Yuki Ichinose
AU  - Akihiro Fujimoto
AU  - Asami Nukui
AU  - Aya Asano
AU  - Hideki Yokogawa
AU  - Masahiro Ohara
AU  - Kazuo Matsuura
AU  - Takahiro Hasebe
AU  - Nobuko Fujiuchi
AU  - Akihiko Osaki
AU  - Toshiaki Saeki
PY  - 2026
JO  - Cancer Medicine
DO  - 10.1002/cam4.72457
UR  - https://doi.org/10.1002/cam4.72457
ER  -

APA

Shimada, H., Todo, M., Ishiguro, H., Mikami, E., Inohana, W., Kurosawa, T., Nakame, A., Sakakibara, A., Ichinose, Y., Fujimoto, A., Nukui, A., Asano, A., Yokogawa, H., Ohara, M., Matsuura, K., Hasebe, T., Fujiuchi, N., Osaki, A., & Saeki, T. (2026). Efficacy and Safety of Datopotamab Deruxtecan From a Single‐Institution Experience in Hormone Receptor–Positive, <scp>HER2</scp> ‐Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody–Drug Conjugates. Cancer Medicine. https://doi.org/10.1002/cam4.72457

Source records

crossref · retrieved 2026-11-08T19:54:15.774Z